Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1570927

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1570927

Huntingtons Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

PUBLISHED:
PAGES: 112 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global Huntington's Disease Treatments Market was valued at USD 457.5 million in 2023, with a projected CAGR of 20.8% over 2024-2032. This growth is fueled by the increasing prevalence of Huntington's disease and significant advancements in medical research. Improved diagnostic tools and greater awareness have led to the identification of more cases, driving the demand for effective treatments. Advances in genetic testing now enable earlier and more accurate diagnoses, facilitating timely interventions. The availability of generic versions of key medications, such as tetrabenazine, has made treatments more affordable and accessible. Additionally, increased funding and investment from governments, pharmaceutical companies, and private investors, are accelerating the discovery and development of new therapies, further contributing to market expansion.

The overall huntingtons disease treatment industry is classified based on the drugs, type, distribution channel, and region.

The market categorizes drugs into tetrabenazine, deutetrabenazine, and other medications. In 2023, tetrabenazine dominated with a 47.8% market share. Tetrabenazine is effective for managing chorea, a major symptom of Huntington's disease, reducing involuntary movements, and improving motor function. Its early regulatory approval and recognition as a specific treatment for Huntington's disease solidifies its market position. Availability in both branded and generic forms provides cost-effective treatment options, maintaining its significant market share.

The market segments treatments into branded and generic categories. In 2023, the branded segment accounted for USD 258 million, driven by established efficacy and strong brand recognition. Branded medications benefit from comprehensive regulatory approval and frequent endorsements in clinical guidelines, reinforcing their position as standard treatments for various conditions. Extensive marketing campaigns and continued investment in research and development further strengthen the appeal of branded treatments, ensuring they remain at the forefront of medical practice.

In 2023, the North American market for Huntington's disease treatments was valued at USD 183.9 million, with a projected CAGR of 20.7%. North America has a high prevalence of Huntington's disease, coupled with increased awareness and early diagnostic capabilities. Improved diagnostic tools and awareness campaigns have led to higher diagnosis rates and greater demand for effective treatments. In 2023, the U.S. market for Huntington's disease treatments was valued at USD 167.7 million, projected to reach USD 894.4 million by 2032. The U.S. is a hub for pharmaceutical R&D, with significant investments in developing new therapies for Huntington's disease, supporting growth in the region.

Product Code: 10732

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of Huntington's disease
      • 3.2.1.2 Increased research and development activities related to Huntington's disease
      • 3.2.1.3 Growing awareness related to the disease
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Limited availability of effective treatment
      • 3.2.2.2 Stringent regulatory requirement
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drugs, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tetrabenazine
  • 5.3 Deutetrabenazine
  • 5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Bausch Health Companies Inc.
  • 9.2 CHEPLAPHARM Arzneimittel GmbH
  • 9.3 Dr. Reddy's Laboratories Ltd.
  • 9.4 H. Lundbeck A/S
  • 9.5 Hikma Pharmaceuticals PLC
  • 9.6 Lupin Limited
  • 9.7 Neurocrine Biosciences, Inc.
  • 9.8 Sun Pharmaceutical Industries Ltd.
  • 9.9 Teva Pharmaceutical Industries Ltd.
  • 9.10 Upsher-Smith Laboratories, LLC.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!